CASE STUDY

Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation

Benjamin J. Lichtbroun¹, Brian Shinder¹, Tina Gowda Sara¹, Arnav Srivastava¹, Biren Saraiya², Tina M. Mayer², Ryan Cristelli³, Evita Sadimin³, Robert E. Weiss¹, Eric A. Singer¹

¹Section of Urologic Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; ²Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; ³Division of Urologic Pathology, Department of Pathology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

Abstract

Chromophobe renal cell carcinoma (chRCC) is one of the less common types of kidney cancer and generally portends a more favorable prognosis. RCC with sarcomatoid differentiation has a more aggressive clinical course with poor outcomes. Four cases of chRCC with varying degrees of sarcomatoid differentiation were retrospectively reviewed at our institution, and clinicopathologic data as well as clinical courses were reported. Patients with higher degrees of sarcomatoid differentiation and larger tumors at presentation generally had a worse overall survival. chRCC with sarcomatoid differentiation portends a poor prognosis with limited data on systemic treatment options for metastatic disease.

Keywords: chromophobe renal cell carcinoma; immune checkpoint inhibitors; kidney cancer; sarcomatoid

Introduction

Renal cell carcinoma (RCC) remains one of the most commonly diagnosed malignancies in the United States (1). Many histologic subtypes of RCC have been described, with the clear cell RCC (ccRCC) variation accounting for nearly 75% of cases (2). Chromophobe renal cell carcinoma (chRCC) is less common, diagnosed in only 5–10% of renal tumors, and typically confers a more indolent course (3, 4). The presence of sarcomatoid differentiation in RCC, which is seen in approximately 5–10% of cases, is typically associated with a highly aggressive behavior, rapid recurrence, a predilection for metastasis, and an extremely poor prognosis (5). Though sarcomatoid features are most commonly found in ccRCC, small subsets of chRCC tumors harbor these pathologic changes as well.
Available evidence seems to suggest that sarcomatoid differentiation in chRCC confers a poor prognosis, though given the scarcity of this subtype, data is limited (6–8). Thus, optimal treatment pathways are unknown. This report highlights four cases of chRCC with sarcomatoid differentiation at a single institution to add to the body of literature describing this clinical entity.

Methods
Four cases of chRCC with varying degrees of sarcomatoid differentiation were retrospectively reviewed at our institution. Clinicopathologic data and clinical courses are reported.

Results

Case 1
A 47-year-old male developed left-sided flank pain and was found to be anemic with a large left-sided palpable mass in 2010. Computed tomography (CT) revealed an 18 cm left-sided lower pole renal mass with possible colonic involvement and no evidence of metastatic disease. He underwent an open left radical nephrectomy, lymphadenectomy, and bowel resection. Surgical pathology was chRCC with 20% sarcomatoid component. The tumor invaded into the peri-nephric fat, Gerotas fascia, and into the subserosa of the large bowel. The bowel however was uninvolved by tumor. One lymph node was removed and was negative for tumor. Final pathology was T4N0M0. He had an uneventful postoperative course. Due to high risk of progression, he was treated with sunitinib at an outside institution. At our institution, he was started on erlotinib with a PI3K inhibitor (pictilisib) as part of a phase I clinical trial (9). Two months after starting the therapy and 11 months post operation, he was noted to have multiple large retroperitoneal masses and new lung nodules, indicating progression of disease and therefore was switched to everolimus. Fine needle aspiration showed poorly differentiated carcinoma. The disease continued to progress, and the patient ultimately died 15 months after his initial surgery at an outside hospital.

Case 2
A 51-year-old female initially presented with right flank and chest pain in 2016. Workup for which revealed a 29 cm right renal mass believed to be eroding into the liver. The mass was biopsied percutaneously showing sarcomatoid tumor. It was unclear at that time if it was RCC or urothelial carcinoma. She was also found to have a right pleural effusion requiring chest tube placement, with cytology from the pleural fluid negative for malignancy. Further workup included a bone scan and MRI brain, which did not reveal any evidence of metastatic disease. She underwent an open right radical nephrectomy with en bloc right hepatectomy, resection of right hemidiaphragm, retroperitoneal lymphadenectomy, and cholecystectomy. Pathology was chRCC with 95% sarcomatoid element and direct extension into the adrenal gland and liver, with 3 out of 11 lymph nodes positive for a final pathologic stage of T4N1M0. There was a positive posterior and vascular margin. Her postoperative course was complicated by a pulmonary embolism, biliary leak, vancomycin-resistant enterococci (VRE) bacteremia, and delirium. She was discharged to rehab on postoperative day 24 and returned 2 days later due to a desaturation event at the rehab accompanied by fevers. Repeated CT showed progression of disease with peritoneal implants along the ascending colon and cecum, a mass on the right psoas muscle, and multiple pleural-based masses along the right costophrenic angle. The patient developed urosepsis and subsequent septic shock and died 60 days after the index procedure.

Case 3
A 63-year-old male initially presented with 3 weeks of severe abdominal pain in 2017. Workup revealed a 26 cm renal mass involving the lower pole of the right kidney with no evidence of metastatic disease. The mass was biopsied percutaneously, which showed only chRCC. During the same hospital stay, he underwent an open right radical nephrectomy that necessitated a right hemicolectomy with a small bowel resection with primary anastomosis. Pathology was chRCC with 65% sarcomatoid element, with 0 out of 2 lymph nodes positive for a final pathologic stage of T4N0M0. There were negative margins. Four months after the index surgery, he developed significant abdominal distension. CT showed a new necrotic 17 cm peritoneal mass as well as significant ascites and a small bowel obstruction. He was started on total parenteral nutrition and was given a venting PEG tube. The patient received one cycle of nivolumab prior to being admitted. Five weeks after starting nivolumab and 161 days after his initial surgery, the patient died of septic shock of unclear etiology.

Case 4
A 51-year-old female initially was noted to have an incidental left renal mass on workup for appendicitis in 2015. At that time, it was biopsied at an outside hospital and was interpreted as an oncocytoma. In 2018, her primary care physician noted a mass in the left upper quadrant during a routine visit and sent her for a CT, which was notable for a 15 cm lower pole renal mass with bulky left retroperitoneal adenopathy. Further workup included a brain MRI, CT chest, and nuclear medicine bone scan, which was notable for only
a small pericardial effusion and also an area of questionable uptake in the left lower sternum (no evidence of bony metastasis on CT imaging). A repeat percutaneous biopsy was performed, which showed only chRCC. She ultimately underwent an open left radical nephrectomy, retroperitoneal lymphadenectomy, and umbilical hernia repair. Pathology was chRCC with focal sarcomatoid features. A large 19 cm lymph node packet in the pre- and para-aortic regions was positive for chRCC for a final stage of T3aN1. Surgical margins were negative. She had an uneventful postoperative course. Follow-up imaging 14 months post operation revealed new retroperitoneal lymphadenopathy with a 1.4 cm lesion posterior to the left psoas as well as new adenopathy in the neck and mediastinum region. Biopsy confirmed recurrence of the disease. She was started on pembrolizumab and axitinib shortly after the diagnosis of disease recurrence and was maintained on it for 2 years—200 mg pembrolizumab every 3 weeks and 5 mg axitinib daily. Restaging scan 2 years after starting systemic therapy showed worsening abdominopelvic and thoracic lymphadenopathy, prompting a treatment change to cabozantinib at her last visit, that is, 40 mg daily. At last follow-up, the patient is 44 months from her index surgery.

**Histology and immunochemistry**

In cases 2 and 3, the tumors showed areas with classic chRCC morphology (Figure 1A), composed of oncocytic cells with abundant clear to granular cytoplasm, perinuclear clearing, and irregular nuclear contours. The sarcomatoid areas showed spindle cells with fascicular and storiform growth patterns (Figure 1B). At the area of transition from the classical morphology to the sarcomatoid morphology (Figure 1C) in one of our cases, the sarcomatoid component showed loss of CK7 immunostaining, which is diffusely positive in the adjacent chromophobe component (Figure 1D). Both tumors had extensive necrosis and extended beyond the kidney. In Case 2, the tumor invaded through the kidney, through the adjacent adrenal gland, and into the liver. Multiple lymph nodes were positive for metastasis. While in Case 3, the tumor invaded through the kidney into the perinephric tissue, adjacent

![Figure 1](image-url)

**Figure 1:** (A) Area of the tumor showing more typical chromophobe renal cell carcinoma morphology, low magnification; (B) Area of the tumor showing the sarcomatoid morphology, low magnification; (C) Transition area with (D) CK7 immunostain highlighting the chromophobe component while negative in the sarcomatoid component.
small bowel wall, and into the mesentery. There was no lymph node involvement.

Discussion

While ccRCC is the most common histologic subtype of RCC, chRCC comprises roughly 5–10% of the cases and generally portends a better prognosis (3, 4). Localized chRCC is generally treated with surgery and at 5 years has a recurrence-free survival (RFS) of 89.3% and a cancer-specific survival (CSS) rate of 93% (10). chRCC with sarcomatoid features generally portends a poor prognosis when compared to the relatively indolent nature of chRCC (3, 4, 6, 8, 11). While chRCC is one of the less common subtypes of RCC, the combination of chRCC with sarcomatoid differentiation presents a uniquely rare clinical entity. Because of the relative rarity of metastatic chRCC, prospective trials are generally not available, and patients with this clinical entity are often grouped together as “non-ccRCC.” While there have been many advances in the treatment of metastatic ccRCC, therapeutic advances in non-ccRCC have been somewhat limited due to low incidence and limited clinical trial success (12). The National Comprehensive Cancer Network (NCCN) recommends enrollment in a clinical trial for patients with metastatic non-ccRCC with other preferred regimens including tyrosine kinase inhibitors such as cabozantinib and sunitinib (13).

In this case series, we discuss four patients with chRCC with sarcomatoid features who presented in their fourth through sixth decades of life (Tables 1 and 2). In our cohort, patients who had a larger percentage of sarcomatoid differentiation generally had a shorter overall survival (OS), while patients who had a small percentage of sarcomatoid component generally lived longer. One patient had only focal sarcomatoid component and is still alive 44 months after surgery. On the other hand, a patient with 95% sarcomatoid component died 60 days following surgery, and she had a complicated postoperative course with early recurrence. In addition, our patients who had a larger sarcomatoid component also had a larger tumor size at presentation. These findings are similar to the previous study reports on chRCC with sarcomatoid differentiation (6–8).

In a recent study by Casuscelli et al., they reviewed the clinicopathological parameters of all patients diagnosed with chRCC between 1990 and 2016 and compared them to patients with ccRCC. There were a total of 496 patients with chRCC and 3,312 patients with ccRCC included. Their findings revealed that patients with larger tumors and those with sarcomatoid differentiation were more likely to have metastatic development, decreased RFS, and decreased OS (11). A multicenter dataset evaluated prognostic factors for RFS and CSS in patients with chRCC. Out of 5,463 patients surgically treated for RCC, 91 had chRCC. They found that in addition to male gender and stage of the disease, sarcomatoid differentiation was an independent predictor of worse RFS and CSS (10).

Previous studies also found that in patients with RCC, the percentage of sarcomatoid component was associated with poorer outcomes (14). A recent study by Ged et al. retrospectively assessed patients with metastatic chRCC and compared outcomes between patients with and without sarcomatoid differentiation. They found that after nephrectomy, the sarcomatoid group had quicker time to treatment failure and decreased OS (38 months vs 7.5 months) (6). A study by Pieretti et al. looked at the long-term outcomes in patients with chRCC. They placed patients with sarcomatoid RCC or lymph node–positive disease into the high-risk category and compared them to patients without these findings. They found that only 10 patients out of 300 had sarcomatoid differentiation. They found that the high-risk group had higher risk of recurrence, that is, 50% versus 4.9% lower 10-year RFS, that is, 91.4% versus 34.4%; and lower 10-year CSS, that is, 96.4% versus 54.3% (15).

As various chemotherapeutic regimens have shown efficacy in other types of sarcomas, multiple studies have attempted to extrapolate these findings to sarcomatoid RCC. The combination of gemcitabine and doxorubicin has shown some activity in patients with RCC with sarcomatoid features (16, 17). Sunitinib in combination with gemcitabine was also investigated in patients with sarcomatoid or poor-risk metastatic RCC, and the authors found that the combination of both medications was better than either one alone (18). The combination of bevacizumab with capcitabine and gemcitabine is also being investigated—although there are low response rates, it has been well tolerated (18, 19).

While sarcomatoid differentiation generally portends a worse prognosis in RCC, it does have a unique immunologic landscape with frequent expression of program death ligand-1 (PD-L1) (20). Targeting this pathway has shown clinical benefit in the setting of metastatic ccRCC with sarcomatoid features, making this an attractive target for future clinical trials for metastatic chRCC (20, 21). It is also worth noting that the one patient in our cohort who received a combination of pembrolizumab and axitinib is still alive 44 months after surgery. While she of course only had focal sarcomatoid features, it highlights the recent advances in systemic therapy in treating these patients. With the treatment landscape for metastatic and advanced RCC changing, including immune checkpoint inhibitors (ICI) as a staple of treatment, there has been much discussion surrounding the use of these treatment modalities for patients with sarcomatoid differentiation. A recent meta-analysis and systematic review evaluated the six published Phase III randomized controlled trials evaluating ICI-based combination therapy for metastatic RCC. Five out of these six studies presented data on the subset of patients with ccRCC with sarcomatoid
features, a total of 568 patients. In all five studies, there was a significantly improved progression-free survival (PFS) and improved objective response rate with combination ICI therapy compared to sunitinib. The combination of nivolumab and ipilimumab achieved the highest complete response rate, and the combination of nivolumab and cabozantinib had the highest likelihood of improvement in PFS and OS (22). Unfortunately, it remains to be seen whether such treatment advances are applicable to patients with chRCC and sarcomatoid differentiation given the relative rarity of this combination. Sarcomatoid and rhabdoid RCC tumors have also been found to have unique molecular markers, which may account for their aggressive nature. In addition to their unique genomic and transcriptomic features, these tumors also exhibit an immune-inflamed phenotype, which may account for the responsiveness to ICIs (23). With the positive results in these recent studies, it begs the question whether a deferred surgery should be considered in patients who are excellent responders to one of these combination therapies or if these medications should be considered largely palliative.

The exact mechanism of sarcomatoid dedifferentiation is unclear. One theory, called the epithelial-mesenchymal
Table 2: Summary of existing literature on patients with chRCC with sarcomatoid features within the last 10 years.

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Primary endpoint</th>
<th>Outcome</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ged et al.</td>
<td>29</td>
<td>RFS</td>
<td>RFS was shorter in patients with sarcomatoid features than without – 2.7 months (95% CI, 0.7–6.9) vs 48.8 months (95% CI, 30.8–80.7, P &lt; 0.001)</td>
<td>Retrospective review of 109 patients with metastatic chRCC. 29 patients with a sarcomatoid component were compared to those without</td>
</tr>
<tr>
<td>Pieretti et al.</td>
<td>10</td>
<td>CSS, RFS</td>
<td>10-year RFS was 91.4% in high risk group and 34.4% in low risk group (P &lt; 0.001). 10-year CSS was 96.4% in the low-risk group and 54.3% in the high risk group (P &lt; 0.001). Sarcomatoid features was independently associated with RFS (HR 5.5, 95% CI 1.5–20.2, P = 0.01)</td>
<td>Retrospective review of 300 patients with sporadic, unilateral, nonmetastatic chRCC. Patients with sarcomatoid features or nodal disease were considered high risk</td>
</tr>
<tr>
<td>Casuscelli et al.</td>
<td>6</td>
<td>RFS, OS</td>
<td>In univariate analysis with patients with sarcomatoid differentiation, OS (HR 38.686, 95% CI 14.721–101.662, P &lt; 0.001) and RFS (HR 40.747, 13.363–124.245, P &lt; 0.001) were both significantly shorter</td>
<td>A prospectively maintained database was queried to compare 3312 patients with ccRCC to 496 patients with chRCC who were surgically treated and clinicopathologic characteristics were compared</td>
</tr>
<tr>
<td>Volpe et al.</td>
<td>5</td>
<td>RFS, CSS</td>
<td>On univariable analysis, sarcomatoid differentiation was associated with decreased CSS (HR 25.9, 95% CI 8.1–83.1, P &lt; 0.001) and decreased RFS (HR 18.2, 95% CI 6–55, P &lt; 0.001)</td>
<td>291 patients with chRCC were identified in a retrospective database of patients surgically treated for RCC from 1995 to 2007, and cancere-related outcomes and prognostic factors for chRCC were assessed</td>
</tr>
<tr>
<td>Cheville et al.</td>
<td>13</td>
<td>CSS</td>
<td>On univariate analysis, sarcomatoid differentiation was associated with decreased CSS (HR 45.88, 95% CI 15.55–135.38, P &lt; 0.001)</td>
<td>Pathologic features of 185 patients with chRCC who were surgically treated between 1970 and 2006 were reviewed</td>
</tr>
<tr>
<td>Lauer et al.</td>
<td>14</td>
<td>OS</td>
<td>10 out of 14 patients died of the disease. 9 died within the first 6 months since surgery; mean survival of 10 weeks.</td>
<td>Surgical pathology from 14 patients with chRCC with sarcomatoid features were retrospectively reviewed and clinicopathologic features assessed</td>
</tr>
<tr>
<td>Przbycin et al.</td>
<td>4</td>
<td>5-year cumulative incidence of events – local recurrence or metastasis</td>
<td>1 out of the 4 patients had a metastasis and zero had a local recurrence (HR 33.3, 95% CI 0.9–77.4, P = 0.02)</td>
<td>A prospectively maintain database was queried and 203 patients with chRCC who were surgically treated between 1988 and 2006 were identified and clinicopathologic characteristics were assessed</td>
</tr>
</tbody>
</table>

ccRCC, clear cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; CSS, cancer-specific survival; OS, overall survival; RFS, recurrence-free survival.

transition (EMT), posits that tumors with a sarcomatoid component have two separate cell lines within the tumor—an epithelial component and a mesenchymal component (24). Evidence suggests that the mesenchymal component, which gives rise to the sarcomatoid features, starts from the same cell line as the epithelial component. This process is seen in normal development in order to create different types of specialized tissue; however, it can also be seen with tumor development (24).
This data also highlights the limitations of percutaneous renal mass biopsy, as one of our patients was noted to have chRCC on biopsy and it was not until after surgery that he or she was found to have a significant percentage of sarcomatoid component. A second patient had her initial biopsy at an outside hospital, which was thought to be an oncocyto ma and 3 years later had a repeat biopsy that revealed only chRCC. Given that percutaneous renal mass biopsies sample a small area, future research will need to investigate better imaging modalities in order to detect sarcomatoid features (25). Physicians should also have a high level of suspicion for sarcomatoid features when the renal mass biopsy shows a more indolent pathology, but the tumor biology appears aggressive in nature with a large tumor burden, lymphadenopathy, or metastatic disease.

Much of the data relating to RCC with sarcomatoid features is in patients with clear cell pathology. chRCC generally portends a more favorable prognosis with different tumor biology, making comparisons between the two histologies challenging. While ICIs for ccRCC with sarcomatoid features has shown promise in the metastatic setting, there is limited data on this in the adjuvant setting, making this an opportunity for further research (26). As we begin to understand the tumor molecular markers of sarcomatoid RCC, it is important to note the differences between clear cell and non-clear cell pathology.

There are multiple ongoing trials evaluating whether ICIs may be beneficial for patients was RCC with sarcomatoid features. This cohort also highlights the need for improved detection of sarcomatoid features as percutaneous renal mass biopsy and current imaging modalities often are unable to detect this unfavorable pathology. Future trials are needed to specifically evaluate patients with non-clear cell RCC and those with sarcomatoid differentiation. Further, clinicopathologic and translational aspects of chRCC need to be studied to aid in future prognosis and management of these patients (27–30). The affected patients may also benefit from adjuvant therapy given the high risk of disease recurrence after surgery.

**Conclusion**

chRCC is a less common form of kidney cancer that is often very indolent and can be treated with surgical resection. An even less common clinical scenario is when patients with chRCC have components of sarcomatoid differentiation, which has a much more aggressive course. Here, we presented four patients in their fourth to sixth decades of life, who had chRCC with varying degrees of sarcomatoid component. In our patients, it was observed that those who had a larger degree of sarcomatoid component and larger tumor size at presentation had a worse outcome, which is in line with recent reports. Future clinical trials are required in order to determine optimal systemic therapy regimens for these patients.

**Conflicts of Interest**

All conflicts of interest, including specific financial interests and relationships and affiliations relevant or not relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are as follows:

Singer EA: Astellas/Medivation: Research support to institution; Johnson & Johnson: Advisory board; Merck: Advisory board; Vyriad: Advisory board; Aura Biosciences: Data safety–monitoring board; Saraiya B: Merck, Regeneron: Research support to institution.

**Ethics Statements**

The authors are accountable for all aspects of this work in ensuring that questions related to the accuracy or integrity of this work are appropriately investigated and resolved. This study was exempt from IRB review. Exclusively de-identified data was utilized.

**Funding**

This work was supported by a grant from the National Cancer Institute (P30CA072720).

**References**

Lichtbroun BJ et al.


